Review on Pharmacophore Mapping And Virtual Screening

Sweta Katore[1], Dr Prachi Kanawade[2], Dr Jaydeep Pawar[3], Rohini bairagi[4]
[1, 2, 3, 4] Dept of Chemistry

Abstract- *3D pharmacophore-based techniques are crucial for virtual screening of large compound databases. They offer an intuitive approach but pose algorithmic challenges. This review discusses strategies and algorithms used in pharmacophore modeling platforms, high lighting their differences. Virtual screening helps predict molecule activity, reducing costs and resources needed for drug development by identifying promising leads for lab experiments.*

Pharmacophore models can be developed when a protein target's 3D structure is unknown or when ligands are available. These models, based on chemical features like hydrogen-bond acceptors/donors, are used for virtual screening of databases.3D pharmacophores consider featureslikehydrophobicpoints,acidic/basicgroups,andhydrogenbonding.Virtualscreening with 3D pharmacophores requires advanced tools due to increased complexity. The chemical function-based approach is widely used, defining inter actions between molecules and proteins

I. INTRODUCTION

3D pharmacophores consider features like hydrophobic points, acidic/basic groups, and hydrogen bonding. Virtual screening with 3D pharmacophores requires advanced tools due to increased complexity. The chemical function-based approach is widely used, defining interactions between molecules and proteins.

Methods for pharmacophore generation :

There are two methods for pharmacophore generation:

1. Direct method: Uses both ligand and receptor information.
2. Indirect method: Uses only ligand information, advantageous when receptor structure is unknown .

Pharmacophore identification involves six steps:

1. Input
2. Conformational Search
3. Feature extraction
4. Structural representation
5. Pattern Identification
6. Scoring

Ligand Type

Key considerations for input selection include:

Type of ligand molecules

1. Size of the data set
2. Diversity of the data set

These factors significantly impact the resulting pharmacophore model.

Data Set size:

Most pharmacophore methods handle small datasets (<100 ligands), which is suitable for early- stage projects with limited ligand data.

Data Set Diversity :

For accurate pharmacophore modeling:

1. Diverse dataset is preferred to identify critical binding features.
2. Outliers should have minimal influence on the model.
3. Higmodels. Balance diversity with relevance is key.

Conformational Search:

The conformational search problem is complicated because ligands are flexible molecules with many possible conformations due to the rotation of molecular parts around single bonds, and each conformation may bind in the active site of the receptor.

Feature Extraction :

feature extraction in pharmacophore analysis involves identifying relevant features in a molecule, which can be achieved through atom-based, topology-based, or function-based approaches, with function-based methods focusing on

chemical functional features like hydrogen bond acceptors and donors.

Structural Representation :

hly diverse ligands may bind at different sites, potentially leading to incorrectPharmacophore identification involves:

1. Structure Representation: Combining selected features to represent each ligand.
2. Pattern Identification: Involves stages like:
    - Constructive stage: Identifies common pharmacophore candidates among most active ligands.



Process:

- Determines top active compounds.
- Performs exhaustive search on conformations.
- Retains candidates fitting a minimum subset of features.

Diversity of the dataset impacts the resultingpharmacophore candidates. Pharmacophore generation involves:

1. Subtractive stage: Removes candidates present in >50% of least active ligands.
2. Optimization stage: Improves candidate scores via simulated annealing.

These stages refine pharmacophore model

Pharmacophore scoring:

1. Ranks candidates based on likelihood of non-chance correlation.
2. Considers feature rarity (e.g., charged centers are rarer than hydrophobic features).
3. Accounts for partial fits and weights infrequent features (e.g., negative charge centers).

This scoring scheme helps prioritize pharmacophore model Similarity-based virtual screening:

1. Predicts molecule properties based on similarity to known binders.
2. Uses efficient methods to screen large databases (e.g., PubChem) for similar molecules.
3. Represents molecules as fingerprints or SMILES strings.

This approach identifies potential ligands by similarity to known binders, without requiring extensive docking simulations.

II. CONCLUSION

1. Pharmacophore modeling: Useful when protein structure is unknown.
2. Helps identify essential molecular features for activity.
3. Predictive in evaluating new compounds.

Future improvement areas:

1. Memory usage optimization.
2. I/O efficient implementation for large databases.

REFERENCES

[1] Hert, J. et al. (2004) Comparison of fingerprint- based methods for virtual screening usingmultiple bioactive reference structures. J.Chem. Inf. Comput. Sci. 44, 1177–1185
[2] Willet, P. (2005) Searching techniques for databases of two three dimensional chemical structures. J. Med. Chem. 48, 4183–4199
[3] Humblet, C. and Dunbar, J.B., Jr (1993) ChapterVI. Topics in drug design and discovery. In Annual Reports in Medicinal Chemistry, (Vol. 28) (Venuti, M.C., ed.), pp. 275–284.
[4] Evers, A. et al. (2005) Virtual screening of biogenic amine-binding Gproteincoupled receptors: comparative evaluation of protein-and ligandbased virtual screening protocols. J. Med. Chem. 48, 5448–5465
[5] 38 Hurst, T. (1994) Flexible 3D searching: the directed tweak technique. J. Chem. Inf. Comput. Sci. 34, 190–196.
[6] Wolber, G. et al. (2006) Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput.- Aided Mol. Des. 20 (12), 773–788.
[7] Sheridan, R.P. and Kearsley, S.K. (2002) Drug Discov. Today 7, 903–911.
[8] Johnson, M.A. and Maggiora, G.M. (1990) Concepts and Applications of Molecular Similarity. John Wiley & Sons, Inc. Leach, A

[9] Mason, J.S. et al. (2001) 3-D pharmacophores in drug discovery. Curr Pharm. Des. 7, 567–597